Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.

Launched by UNIVERSITY OF MILANO BICOCCA · Sep 21, 2022

Keywords

ClinConnect Summary

The INFLA-ME Study is a clinical trial designed to better understand how inflammation affects patients with a type of blood cancer known as ph-negative myeloproliferative neoplasms (MPNs). Researchers are looking at certain markers in the blood that indicate inflammation and how these markers change over time in patients. The goal is to see if there’s a link between these inflammatory markers and important health events, like blood clots or changes in the disease's progression. This could help doctors identify patients at higher risk for complications and improve treatment strategies.

To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of specific types of MPNs, such as polycythemia vera (PV) or essential thrombocythemia (ET), since the year 2000. Participants will need to provide informed consent, which means they agree to take part in the study after being fully informed about what it involves. The study is currently recruiting participants, and it is important to note that those with a life expectancy of less than six months or certain advanced stages of the disease may not be eligible. Taking part in this study could help advance our understanding of MPNs and lead to better care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years at the time of diagnosis of MPN Ph negative
• • Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000)
• • Obtaining informed consent
• Exclusion Criteria:
• • Life expectancy of less than 6 months
• • Accelerated phase myelofibrosis or MPN with signs of leukemic evolution